We predicted two GINS2 inhibitors with the most minor scores in both the TCGA and Chinese Glioma Genome Atlas databases: Palbociclib (Pal) and BIX-02189 (Fig. 7A). This evidence concerns the gene GINS2 and central nervous system cancer.